Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review
Yair Lotan(Southwestern Medical Center), Ellen C. Zwarthoff(Erasmus MC), Siamak Daneshmand(Unknown), Peter C. Black(University of British Columbia), Michael S. Cookson(University of Oklahoma Health Sciences Center), Laura Caba, Gary D. Steinberg(Rush University Medical Center), Chad R. Ritch(University of Miami), Raj S. Pruthi(University of North Carolina at Chapel Hill), Robert S. Svatek(The University of Texas at San Antonio Health Science Center), Sam S. Chang(Vanderbilt University), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center)
Cited by 30
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo.
|Proceedings of the National Academy of Sciences|1989|493